AMALY — SHARIAH COMPLIANCE REPORT ================================== Symbol: PMVP Report Date: 2026-09-30 Full Report: https://amaly.io/stock/PMVP EXECUTIVE SUMMARY ------------------ Compliance Status: NON_COMPLIANT Quality Rating: B Description: PMV Pharmaceuticals, Inc. (PMVP) is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting p53 mutations. The core business activity in cancer treatment development is Shariah-compliant, aligning with Islamic principles of preserving life. However, financial screening reveals non-compliance primarily due to an excessively high liquidity ratio (244.3%) exceeding thresholds across AAOIFI, MSCI, and S&P standards, indicating potential riba exposure in cash management. No non-permissible income or significant debt issues are present. Overall, while business activities are permissible, the stock is classified as NON_COMPLIANT based on index exclusions and quantitative failures. Primary Compliance Concerns: - High liquidity ratio (244.3%) exceeds all major thresholds, potentially indicating interest-bearing cash holdings - Insufficient data for precise non-permissible income assessment, though estimated at 0% Purification Requirement: 0.00% Index Inclusion: Not included in any of the major Shariah-compliant indices (S&P, MSCI, FTSE, DJIM) KEY FINANCIAL METRICS ---------------------- Debt Ratio: 1.7% Liquidity Ratio: 244.3% Interest Income Ratio: 0.0% Purification Required: 0.00% INDEX INCLUSION STATUS ----------------------- S&P Shariah: EXCLUDED MSCI Islamic: EXCLUDED DJIM: EXCLUDED FTSE Shariah: EXCLUDED Total: 0 of 4 Last Verified: 2025-11-30 REPORTING PERIOD ----------------- Latest Annual Report: FY 2025 Latest Quarterly Data: Q4 2025 Trend Period: FY 2020 to FY 2025 Data Retrieved: 2026-02-28T00:00:00Z --- Full interactive report: https://amaly.io/stock/PMVP Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.